Missouri AG warns Lilly over 340B data demands; House probes PBM audits

· Health · United States

Missouri's attorney general told Eli Lilly to stop forcing hospitals to provide claims data in order to receive discounted medicines under the 340B program, a sign that more states are pushing back against drugmakers' conditions on the federal discount scheme. Separately, a House lawmaker is investigating whether the three largest pharmacy benefit managers targeted independent pharmacies with retaliatory or punitive audits. Both developments add to mounting scrutiny of how discounts and audits flow through the US drug supply chain, with hospitals, independent pharmacies, drugmakers and PBMs all pressing their cases to regulators and lawmakers.

Why it matters：The 340B program and PBM audit practices move billions in drug spending, and state-level pushback plus congressional scrutiny could change the conditions under which hospitals and pharmacies buy and dispense medicines.

Key points

  • Missouri's AG says Lilly should stop requiring claims data from hospitals for 340B discounts.
  • A House lawmaker is probing whether the largest PBMs used punitive audits against independent pharmacies.
  • Both issues concern how discounts and audits work in the US drug supply chain.

Sources (original reporting)

More stories from this day